Research programme: IRAK-4 inhibitors - Aurigene/Curis

Drug Profile

Research programme: IRAK-4 inhibitors - Aurigene/Curis

Alternative Names: CA-4948; Interleukin-1 receptor-associated kinase 4 inhibitors - Aurigene/Curis; IRAK-4 inhibitors; IRAK4 kinase inhibitors - Aurigene/Curis

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Discovery Technologies; Curis
  • Class Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Inflammation

Most Recent Events

  • 29 Feb 2016 Curis plans a phase I trial for Haematological malignancies in USA (Curis, Form 10-K, February 2016)
  • 07 Oct 2015 Curis exercises its option to exclusively license small molecule antagonists of Interleukin-1 receptor-associated kinase 4 (IRAK4)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top